<DOC>
	<DOCNO>NCT00083005</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel estramustine , work different way stop tumor cell divide stop grow die . Thalidomide may stop growth prostate cancer stop blood flow tumor . Giving chemotherapy together thalidomide may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel estramustine together thalidomide work treat patient androgen-independent metastatic adenocarcinoma ( cancer ) prostate .</brief_summary>
	<brief_title>Docetaxel , Estramustine , Thalidomide Treating Patients With Androgen-Independent Metastatic Adenocarcinoma Prostate</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine prostate-specific antigen response patient androgen-independent metastatic adenocarcinoma prostate treat docetaxel , estramustine , thalidomide . Secondary - Determine survival duration patient treat regimen . - Determine pharmacokinetics docetaxel thalidomide patient treated regimen . - Determine whether pharmacodynamic relationship exist plasma concentration docetaxel and/or thalidomide clinical activity toxicity regimen patient . - Determine existence quantification circulate prostate cancer cell patient treatment regimen . - Determine genotype , regard cytochrome P450 2C19 polymorphism , patient treat regimen . - Correlate genotype pharmacokinetics efficacy regimen patient . - Determine change molecular marker angiogenesis ( include , limited , serum urine vascular endothelial growth factor ) patient treatment regimen . - Determine toxicity profile regimen patient . OUTLINE : This open-label study . Patients receive docetaxel IV 30 minute day 2 , 9 , 16 , oral thalidomide daily day 1-28 , oral estramustine three time daily day 1-3 , 8-10 , 15-17 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 33-60 patient accrue study within 11-20 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Metastatic disease Androgenindependent disease Clinically progressive disease document least 1 follow parameter : Two consecutively rise prostatespecific antigen ( PSA ) level take least 1 week apart PSA ≥ 5.0 ng/mL Continued rise PSA 4 week discontinuation prior flutamide OR 6 week discontinuation prior bicalutamide nilutamide ( patient treat antiandrogen agent ) At least 1 new lesion bone scan Progressive measurable disease Must undergone bilateral surgical castration OR continue gonadotropinreleasing hormone agonist No brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count ≥ 100,000/mm^3* Hemoglobin ≥ 7.5 g/dL* NOTE : *No transfusion within past 2 week Hepatic AST ALT &lt; 2.5 time upper limit normal ( ULN ) Bilirubin &lt; ULN ( ≤ 3.0 time ULN patient Gilbert 's syndrome ) Alkaline phosphatase ≤ 2.5 time ULN OR Fractionated hepatic alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 40 mL/min Cardiovascular No transient ischemic attack cerebrovascular accident within past 2 year No myocardial infarction within past 6 month No uncontrolled congestive heart failure No uncontrolled angina pectoris No thromboembolic disease Other No peripheral neuropathy ≥ grade 2 No cognitive impairment would preclude study participation give informed consent No active malignancy within past 2 year except nonmelanoma skin cancer superficial bladder carcinoma Fertile patient must use effective contraception least 1 month , , least 1 month study treatment PRIOR CONCURRENT THERAPY : Biologic therapy No prior thalidomide Chemotherapy No prior docetaxel No prior estramustine No prior chemotherapy metastatic prostate cancer Endocrine therapy See Disease Characteristics Radiotherapy Recovered prior radiotherapy Surgery See Disease Characteristics Recovered prior surgery Other No concurrent antiretroviral therapy HIVpositive patient No concurrent complementary alternative therapy would interact study drug No concurrent herbal nutritional product dietary supplement would interact study drug No concurrent aprepitant secondary prophylaxis antiemetic treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>